Ivonescimab for untreated extensive-stage SCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- You cannot have received any previous treatment for this stage of lung cancer (like chemotherapy).
- You must be between 18 and 75 years old.
- You must be generally active and able to take care of yourself (ECOG score 0 or 1).
- You cannot have active or untreated brain tumors, serious heart disease, bleeding problems, or certain infections like hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy followed by targeted chest radiation as the first treatment for extensive-stage small cell lung cancer. The goal is to see if adding radiation after chemo-immunotherapy works better than standard treatment alone.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.